9% revenue growth and 18% EBITDA margin
Xellia Pharmaceuticals (‘Xellia’), the specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has announced its full year results for the year ended 31 December 2015.
The Company reported a 9% increase in revenue to USD 220.2m (2014: USD 201.4m). EBITDA was up to USD 40.7m (2014: USD 11.7m). Xellia made good progress in 2015, securing additional manufacturing capacity for its injectable anti-infective products and resolving a production issue at its Copenhagen site to meet operational targets, whilst continuing to focus on innovation.
The standout event of the year was the acquisition of sterile injectable manufacturing facilities in Bedford, Ohio from Hikma Pharmaceuticals in November. Xellia is working closely with the US FDA and investing considerably in these facilities to establish a new cGMP organization to begin commercial production by the end of 2017.
The increase in revenue was predominantly attributed to sales of Xellia’s portfolio of anti-infective final dosage form (FDF) products including effects of the Raleigh acquisition in 2014. In 2015, 42% of the Company’s sales were of FDFs compared to 33% in 2014. This is aligned with Xellia’s vertical integration strategy to provide customers with a more balanced portfolio of both the Active Pharmaceutical Ingredients and final drug products.
As additional US manufacturing capacity becomes available, increasing FDF sales will continue, helping to simplify and streamline the supply chain for the Company’s over 500 customers.
Xellia’s EBITDA was USD 40.7m, a significant increase over 2014 (USD 11.7m). In 2015 Xellia has continued to invest considerably in its anti-infective pipeline following a strategic refocus on innovative and proprietary products, posting a total R&D spend of 12% of sales.
In line with expectations, the reported net result ended at a loss of USD 3.6m (2014: (216.1).
Carl-Åke Carlsson, CEO, Xellia said:
“2015 has been a busy and productive year which is reflected in our increased revenue and EBITDA. “We have made great operational progress and have positioned the Company well for continued growth with the acquisition of the Bedford site.
“As we look to the future, we intend to build on this strong platform of manufacturing capacity and innovation excellence. Our strategy is to maximize the potential of our existing world-leading anti-infective products and to expand our portfolio and pipeline further.”
For more information, please contact:
Carl-Åke Carlsson, CEO
Tel: +45 32 64 55 00